pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response

Henry, JA; Nh, Piggott; Uk, Mallick; Nicholson, S; Farndon,; Br, Westley; Fe, May

doi:10.1038/bjc.1991.141

Cited by 107 publications

(72 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…pS2, a small cysteine-rich protein of unknown function, appeared with ER to be strongly correlated with tamoxifen-induced tumour regression. This had already been suggested by others (Henry et al, 1989(Henry et al, , 1991Schwartz et al, 1991;Hurlimann et al, 1993;Wilson et al, 1994). We were unable to show a link between response to tamoxifen and c-erbB-2 or GSTi expression, contrary to previous studies (Wright et al, 1992;Nicholson et al, 1993;Dorion-Bonnet et al, 1993).…”

supporting

confidence: 64%

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Soubeyran

Quénel²,

Mauriac³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

Summary Seventy-four post-menopausal patients with primary non-metastatic invasive ductal carcinomas of the breast were first treated with tamoxifen alone (30 mg p.o. daily) for 5 months. To study changes induced by tamoxifen, core biopsies before treatment and surgical specimens after hormonal therapy were assayed by immunohistochemistry for oestrogen (ER) and progesterone receptors (PR), pS2, GSTh and c-erbB-2. After tamoxifen, ER and PR significantly decreased in 60 and 44 cases respectively, whereas 11 and 19 cases showed no variation and 2 and II cases showed an increase (P< 10-4). GSTir and pS2 showed a significant increase in 43 and 41 cases, a decrease in 2 and 21 cases and no variation in 29 and 12 cases (P<.10-4 and P=0.04 respectively). c-erbB-2 showed no significant variation under tamoxifen, increased in only three cases and decreased in 13 cases. No relation was found between these variations and efficiency of hormone therapy. Our results allow a better knowledge of protein expression modifications occurring in breast cancer cells under tamoxifen therapy. They are also more consistent with clone selection rather than with phenotype modification.

show abstract

supporting

confidence: 64%

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Soubeyran

Quénel²,

Mauriac³

et al. 1996

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…In pilot studies involving 21 patients with recurrent disease, PS2 at the transcriptional level was predictive for endocrine responsiveness (Henry et al, 1989;Skilton et al, 1989). Similar results were obtained with immunohistochemically assessed PS2 status in small series of 35 (Henry et al, 1991) and 72 patients (Schwartz et al, 1991), but these findings were not confirmed by Luqmani et al (1993a) in a study involving 70 patients.…”

supporting

confidence: 62%

“…Similar results with respect to a relationship between PS2 expression and (relapse-free) survival were obtained when PS2 transcripts were analysed (Thompson et al, 1993). On the other hand, immunohistochemically assessed PS2 status was of no or only marginal prognostic value (Henry et al, 1991;Cappelletti et al, 1992;Thor et al, 1992). In pilot studies involving 21 patients with recurrent disease, PS2 at the transcriptional level was predictive for endocrine responsiveness (Henry et al, 1989;Skilton et al, 1989).…”

supporting

confidence: 62%

“…However, no information is currently available in the literature regarding cytosolic PS2 levels and response to endocrine therapy for advanced disease. Irrespective of the technique used to assess PS2, as in the present study, the expression of PS2 in human primary breast tumours has shown to be correlated with that of ER or PgR Henry et al, 1989Henry et al, , 1991Skilton et al, 1989;Foekens et al, 1990Foekens et al, , 1993Schwartz et al, 1991;Cappelletti et al, 1992;Koerner et al, 1992;Predine et al, 1992;Thor et al, 1992;Gion et al, 1993;Luqmani et al, 1993b;Thompson et al, 1993).…”

Section: Discussionmentioning

confidence: 93%

“…One candidate factor could prove to be PS2, a protein which is secreted by breast cancer cells in vitro upon oestrogen stimulation (Masiakowski et al, 1982;Nunez et al, 1987). Indeed, in a few pilot studies involving up to 72 patients, PS2 transcripts (Henry et al, 1989;Skilton et al, 1989) and immunohistochemically assessed PS2 status (Henry et al, 1991;Schwartz et al, 1991) were reported to be predictive for endocrine responsiveness of advanced breast cancer. However, no consensus exists regarding immunohistochemically assessed PS2 status (Luqmani et al, 1993a).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer

Foekens

Portengen²,

Look³

et al. 1994

Br J Cancer

View full text Add to dashboard Cite

PS2, an oestrogen-inducible protein, was measured in the cytosol of 230 primary tumours from patients who were subjected to first-line tamoxifen therapy for advanced disease without prior adjuvant therapy with tamoxifen. PS2 correlated positively with oestrogen receptor (ER, P < 0.01) and progesterone receptor content (PgR, P < 0.001), and with the length of progression-free survival (PFS, P = 0.05). Although not statistically significant, higher levels of PS2 (> or = 10 ng mg-1 protein) were also associated with increased probability of response to tamoxifen treatment and a longer total post-relapse survival (PRS). ER, PgR, menopausal status, site of disease and prior adjuvant chemotherapy were all associated with response to tamoxifen therapy and with PFS. In multivariate analysis for PFS, low levels of ER and PgR, visceral metastasis, a disease-free interval of less than 1 year and prior adjuvant chemotherapy were all significantly associated with an increased probability of a rapid disease progression after start of tamoxifen therapy. In the subset of 83 tumours with intermediate levels of ER and PgR (both > or = 10, but not both > or = 75 fmol mg-1 protein), PS2 was positively related with the length of PFS (P < 0.01) and PRS (P < 0.05). PS2 remained the strongest factor in multivariate analysis for PFS (P < 0.01) in this ER/PgR intermediate subgroup, but was not of predictive value in univariate or multivariate analysis for both PFS and PRS in tumours classified as ER/PgR low or high (> or = 75 fmol mg-1 protein). It is concluded that PS2 status may be used as a parameter, additional to ER and PgR, for better refinement of prediction of response to tamoxifen treatment in advanced breast cancer patients especially with intermediate ER/PgR levels in their primary tumour.

show abstract

Retinoblastoma Protein in Human Breast Carcinoma: Immunohistochemical Study Using a New Monoclonal Antibody Effective on Routinely Processed Tissues

et al. 1996

View full text Add to dashboard Cite

pNR-2/pS2 immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response

Abstract: Summary Expression of the oestrogen-regulated pNR-2/pS2 protein has been studied in paraffin sections

Cited by 107 publications

References 32 publications

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Variation of hormonal receptor, pS2, c-erbB-2 and GSTπ contents in breast carcinomas under tamoxifen: a study of 74 cases

Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer

Retinoblastoma Protein in Human Breast Carcinoma: Immunohistochemical Study Using a New Monoclonal Antibody Effective on Routinely Processed Tissues

Contact Info

Product

Resources

About